CXCR4 in Epidermal Keratinocytes: Crosstalk within the Skin  by Bollag, Wendy B. & Hill, William D.
CXCR4 in Epidermal Keratinocytes:
Crosstalk within the Skin
Wendy B. Bollag1–6 and William D. Hill1,4–6
In this issue, Takekoshi et al. investigated the role of CXCR4 in IL-23-induced
keratinocyte hyperproliferation using an epidermal-specific knockout mouse
model and found that CXCR4 limited keratinocyte proliferation. Some reports
in the literature support this idea, whereas others contradict it; this disparity may
be related to the differential roles of CXCR4 in various cell types or to a recently
identified second receptor (CXCR7). Nevertheless, CXCR4 and its ligand SDF-1
have been implicated in skin wound healing, systemic lupus erythematosus, and
basal cell carcinoma tumor angiogenesis. Further study is merited.
Journal of Investigative Dermatology (2013) 133, 2505–2508. doi:10.1038/jid.2013.271
IL-23 is a cytokine that was recently
found to be involved in the immuno-
pathogenesis of psoriasis (Di Meglio and
Nestle, 2010). Intradermal injection of
IL-23 in mice produces a psoriasi-
form dermatitis, with erythema, epider-
mal hyperplasia, and immune cell
infiltration (Takekoshi et al., 2013, this
issue and reviewed in (Di Meglio and
Nestle, 2010). Elevated IL-23 levels
have been observed in psoriatic lesions
in patients. In addition, a new biologic
agent, ustekinumab (human monoclonal
antibody), that targets a subunit of IL-23
has been used successfully to treat the
disease (Di Meglio and Nestle, 2010).
The chemokine receptor CXCR4 and
its ligand CXCL12, or stromal-derived
factor-1 (SDF-1), are well known for
their roles in hematopoietic stem and
immune cell function. SDF-1 acts as a
signal for the retention of hematopoietic
stem cells in the bone marrow, and the
G-CSF used clinically to mobilize stem
cells from the bone marrow into the
peripheral circulation (brand name Neu-
pogen) is thought to work by triggering
the degradation of SDF-1 (Petit et al.,
2002). However, the possible role of
this axis in skin diseases such as
psoriasis has received only modest
attention to date.
On the other hand, the involvement
of SDF-1 and CXCR4 in skin wound
healing has been investigated in several
laboratories. SDF-1 and/or CXCR4 have
been demonstrated to be upregulated
upon excisional or burn wounding of
skin (Avniel et al., 2006). SDF-1 levels
have been found to increase in
numerous skin wound models of
epidermal function (Toksoy et al.,
2007), and in blister fluid in burn
wounds (Avniel et al., 2006). In the
case of burn wounds, similar results
have been observed in human, pig,
and rat skin, indicating conservation of
that role of the axis (Avniel et al., 2006).
The wounding-induced production of
SDF-1 appears to arise from dermal
fibroblasts rather than from epidermal
keratinocytes, which express the
receptor CXCR4 instead (Avniel et al.,
2006). However, other cells found in
See related article on pg 2530 the wound environment also express
CXCR4, including infiltrating immune
cells and endothelial cells of the
vasculature (Avniel et al., 2006).
In terms of effects on wound healing,
some studies have determined that SDF-
1/CXCR4 signaling delays healing of
excisional and burn wounds, such that
inhibition of the axis using SDF-1-neu-
tralizing antibodies or chemical inhibi-
tors of CXCR4 accelerates their healing
(Avniel et al., 2006; Nishimura et al.,
2012). In contrast, other studies have
determined that topical application of
SDF-1 itself to wound sites enhances
healing (Gallagher et al., 2007; Rabbany
et al., 2010; Henderson et al., 2011;
Sarkar et al., 2011). These disparate
findings are summarized in Table 1.
One confounding factor in identifying
the role of this axis in wound healing
is that elements of the signaling system
are expressed by multiple cell types
involved in wound repair, including
keratinocytes, fibroblasts, and immune
and endothelial cells. Indeed, the ability
to recruit endothelial cells to sites
of injury has also implicated the
axis in angiogenesis (Chu et al., 2009;
Nishimura et al., 2012). Moreover, the
CXCR4/SDF-1 axis is known to be
important in the mobilization of stem
cells from the bone marrow to the sites
of injury (Xu et al., 2013). Therefore,
it is not certain whether the observed
effects of SDF-1/CXCR4 signaling on
wound healing are related to the
resident cells in skin (i.e., keratino-
cytes and fibroblasts) or to infiltrating
immune cells, recruited stem cells, or
the effects on blood supply to the
wound area.
Data in the literature support the
concept that all of these processes
are modulated by the SDF-1/CXCR4
axis. Thus, Florin et al. (2005) have
demonstrated that SDF-1, which is
produced by dermal fibroblasts
through a Jun-dependent effect on its
expression, results in keratinocyte proli-
feration. This effect can be observed
upon treatment of keratinocytes in
feeder-layer coculture with irradiated
fibroblasts, and this is prevented with
neutralizing antibodies to SDF-1 or
CXCR4. Jun-deficient fibroblasts exhi-
bited minimal SDF-1 production, and
in coculture with keratinocytes, they
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induced less keratinocyte proliferation.
This deficiency in keratinocyte proli-
feration could be rescued by adminis-
tration of SDF-1 to the cocultures (Florin
et al., 2005).
In contrast, Avniel et al., (2006) have
suggested that this axis is more involved
in supporting fibrosis than epitheliali-
zation. In addition, these authors have
argued that the ability of the CXCR4
antagonist AMD3100 to accelerate burn
wound healing is related to its capacity
to reduce infiltration of eosinophils into
wound beds, which they propose to
inhibit epithelialization (Avniel et al.,
2006). On the other hand, AMD3100
administration to skin wounds in
diabetic mice increased macrophage
mobilization and activation, as well as
those activities in circulating endothelial
progenitor cells (Nishimura et al., 2012).
This CXCR4 antagonist also accelerated
diabetic wound healing and increased
collagen formation and vascularity at
sites of wounding. Thus, evidence from
this report suggests the effects of the
SDF-1/CXCR4 pathway on fibroblasts,
immune cells, and endothelial cells/
angiogenesis.
Still other groups suggest that SDF-1
enhances wound healing by recruiting
bone marrow–derived mesenchymal
stem cells to wound beds (Xu et al.,
2013). Xu et al. (2013) also report that
the inhibition of SDF-1/CXCR4 signaling
(with blocking/neutralizing antibodies
to CXCR4 and/or to SDF-1) inhibits
neovascularization, a result seemingly
in contrast to a report that has demon-
strated an ability of the CXCR4 antago-
nist AMD3100 to enhance vascularity
(Nishimura et al., 2012). In addition,
Hu et al. (2013) have reported that
AMD3100 pretreatment blocks mesen-
chymal stem cell homing to wound
margins and reduces epithelialization
and wound closure. Additional support
of a proangiogenic role for the axis is
provided by Chu et al. (2009), who have
shown that CXCR4 overexpression in
basal cell carcinoma–derived keratino-
cytes promotes tumor angiogenesis
through a pathway involving extracellu-
lar signal–regulated kinase 1/2 and
NF-kB. In summary, then, the roles of
this axis in skin wound healing and
angiogenesis appear to be opposite,
depending on the study.
It is not clear as to how to reconcile
these disparate results of the SDF-1/
CXCR4 axis on wound healing and
angiogenesis. One possibility is that
inhibition of SDF-1 signaling locally at
sites of injury may affect local cell
survival, proliferation, and/or migration,
as well as the homing of infiltrating
cells, or there may be distant effects on
Clinical Implications
 The SDF-1/CXCR4 axis appears to limit cytokine-induced keratinocyte
proliferation; CXCR4 signaling at the borders of psoriatic plaques may
define the margins of the lesions.
 Similarities exist between SDF-1/CXCR4 signaling in wound healing and
psoriasis, suggesting shared processes between these two skin reactions.
 Dysregulation of SDF-1/CXCR4 signaling after injury in psoriasis-prone
individuals may underlie the Koebner phenomenon.
Table 1. Controversial role of the SDF-1/CXCR4 axis in skin
Role of SDF-1/
CXCR4 axis Reagents used Method of application
Type of injury/model
(system) Reference
Acceleration of
wound healing
(1) SDF-1 in GAG scaffold (1) Topical (1) Excisional wound
(mice)
(1) Sarkar et al. (2011)
(2) SDF-1 in hydrogel (2) Topical (2) Excisional (mice) (2) Rabbany et al. (2010)
(3) SDF-1 in alginate (3) Topical (3) Excisional (mice) (3) Henderson et al. (2011)
(4) SDF-1 (4) Injection into wound
site
(4) Excisional (diabetic
mice)
(4) Gallagher et al. (2007)
(5) SDF-1, SDF-1- and CXCR4-
neutralizing Abs
(5) Exogenous application
or coculture
(5) In vitro (human
keratinocytes, mouse
fibroblasts)
(5) Florin et al. (2005)
Inhibition of
wound healing
(1) CXCR4-neutralizing Ab or
peptide antagonist (TN14003)
(1) SQ (1) Burn wound (mice) (1) Avniel et al. (2006)
(2) CXCR4 antagonist AMD3100 (2) Topical (2) Excisional (diabetic
mice)
(2) Nishimura et al. (2012)
Increased
angiogenesis
(1) CXCR4 overexpression (1) Cell autonomous (1) Human BCC-derived
tumors (mice)
(1) Chu et al. (2009)
(2) CXCR4 antagonist or SDF-1-
neutralizing Ab
(2) Application to stem
cells or injection into
wound
(2) Topical (mice) (2) Xu et al. (2013)
Decreased
angiogenesis
CXCR4 antagonist AMD3100 Topical Excisional (diabetic mice) Nishimura et al. (2012)
Abbreviations: Ab, antibody; BCC, basal cell carcinoma; GAG, glycosaminoglycan; SDF-1, stromal-derived factor-1; SQ, subcutaneously.
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the mobilization of inflammatory and
reparative cells. In addition, Nishimura
et al. (2012) suggest that some of the
observed effects of AMD3100 are
independent of CXCR4. Indeed, it has
been reported that, in addition to
CXCR4, SDF-1 can bind to a second
receptor, CXCR7 (reviewed in Duda
et al., 2011). At this point, investigators
have not reported the expression
patterns or signaling activities of this
receptor, but it seems possible that
some of the effects observed with SDF-
1 and inhibitors of this pathway might
be related to effects mediated through
CXCR7 rather than CXCR4. Indeed,
AMD3100 appears to act as an agonist
at the CXCR7 receptor (Kalatskaya et al.,
2009). CXCR7 has also been implicated
in regulating cell proliferation, adhe-
sion, and migration (reviewed in
Maksym et al., 2009). Furthermore, in
the presence of high levels of SDF-1, the
CXCR4 receptor becomes desensitized,
probably through interaction with b-
arrestin, which is also important in
CXCR4 (and possibly CXCR7) internali-
zation and turnover (Duda et al., 2011).
Therefore, continuous exposure of cells
to SDF-1, for example, perhaps when
topically applied in matrices that protect
the cytokine from degradation, may
result in downregulation of CXCR4
and/or CXCR7. Thus, it will be impor-
tant to distinguish between the effects
mediated by SDF-1-activated processes
and the effects mediated by inhibition of
SDF-1 signaling by downregulation of
its receptor(s).
In this issue of the Journal of Investi-
gative Dermatology, Takekoshi et al.
(2013) describe the generation of an
epidermal keratinocyte–specific knock-
out of CXCR4 by the crossing of floxed
CXCR4 transgenic mice with a keratin
14 promoter–driven Cre recombinase
transgenic mouse model. Using this
model, the authors demonstrated the
involvement of CXCR4 in keratinocytes
in regulating the epidermal keratinocyte
hyperproliferative response to IL-23.
Thus, intradermal injection of IL-23 in
the skin of epidermal-specific CXCR4-
deficient mice resulted in a greater
hyperproliferative response than in
wild-type control mice, suggesting that
SDF-1/CXCR4 signaling normally limits
keratinocyte proliferation in vivo
(Takekoshi et al., 2013). In vitro IL-22
(the downstream mediator of IL-23) sti-
mulates keratinocyte proliferation, and
this effect can be inhibited by co-treat-
ment with SDF-1. IL22’s mechanism
appears to involve increased SOCS3
expression and Stat3 phosphorylation/
activation. Importantly, these authors
also showed reduced CXCR4 and
SOCS3 levels in psoriatic lesions com-
pared with the junctional zone around
lesions (Takekoshi et al., 2013), also
supporting the concept that this pathway
ordinarily limits keratinocyte (hyper)pro-
liferation and suggesting a possible role
in psoriatic pathogenesis. Recently,
Chow et al. (2010) have shown that
keratinocytes, which normally do not
express SDF-1, demonstrate increased
expression not only of SDF-1 but also
of both of its receptors, CXCR4 and
CXCR7, when infected by the human
papilloma virus. This suggests that upre-
gulation of SDF-1/CXCR4(CXCR7) sig-
naling may be a general response of
keratinocytes to injury and other chal-
lenges, including viral infection.
Because epidermal injury can also
trigger the development of psoriatic
lesions, referred to as the Koebner
phenomenon, it seems reasonable to
propose that this axis, indeed, does
have a role in psoriasis.
In addition to the likely involvement
in wound healing and psoriasis, the
SDF-1/CXCR4 axis may also be involved
in other autoimmune-associated skin
diseases. For example, in mouse models
of systemic lupus erythematosus,
CXCR4 antagonists have been demon-
strated to decrease the severity of the
disease, as well as the accompanying
nephritis (reviewed in Chong and
Mohan, 2009). Thus, additional investi-
gation of this important SDF-1/CXCR4/
CXCR7 axis in skin biology is clearly
warranted. The floxed CXCR4 mouse
model used by Hwang and colleagues
(Takekoshi et al., 2013) will be an
important tool for defining the roles of
specific skin cell types in the effects of
SDF-1, CXCR4, and CXCR4 anta-
gonists on cutaneous functions such as
epidermal proliferation, hyperplasia,
and wound healing.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported in part by a VA Research
Career Scientist Award (WBB), VA Merit Awards
(WBB and WDH), and National Institutes of Health
award P01AG036675 (WBB and WDH). The con-
tents of this article do not represent the views of the
Department of Veterans Affairs or the United States
Government.
REFERENCES
Avniel S, Arik Z, Maly A et al. (2006) Involvement
of the CXCL12/CXCR4 pathway in the recov-
ery of skin following burns. J Invest Dermatol
126:468–76
Chong BF, Mohan C (2009) Targeting the CXCR4/
CXCL12 axis in systemic lupus erythematosus.
Expert Opin Ther Targets 13:1147–53
Chow KY, Brotin E, Ben Khalifa Y et al. (2010) A
pivotal role for CXCL12 signaling in HPV-
mediated transformation of keratinocytes: clues
to understanding HPV-pathogenesis in WHIM
syndrome. Cell Host Microbe 8:523–33
Chu CY, Cha ST, Lin WC et al. (2009) Stromal cell-
derived factor-1alpha (SDF-1alpha/CXCL12)-
enhanced angiogenesis of human basal cell
carcinoma cells involves ERK1/2-NF-kappaB/
interleukin-6 pathway. Carcinogenesis 30:
205–13
Di Meglio P, Nestle FO (2010) The role of IL-23 in
the immunopathogenesis of psoriasis. F1000
Biol Rep; 2. pii: 40
Duda DG, Kozin SV, Kirkpatrick ND et al. (2011)
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway
inhibition: an emerging sensitizer for antic-
ancer therapies? Clin Cancer Res 17:2074–80
Florin L, Maas-Szabowski N, Werner S et al. (2005)
Increased keratinocyte proliferation by JUN-
dependent expression of PTN and SDF-1 in
fibroblasts. J Cell Sci 118:1981–9
Gallagher KA, Liu ZJ, Xiao M et al. (2007) Diabetic
impairments in NO-mediated endothelial pro-
genitor cell mobilization and homing are
reversed by hyperoxia and SDF-1 alpha.
J Clin Invest 117:1249–59
Henderson PW, Singh SP, Krijgh DD et al. (2011)
Stromal-derived factor-1 delivered via hydro-
gel drug-delivery vehicle accelerates wound
healing in vivo. Wound Repair Regen 19:
420–5
Hu C, Yong X, Li C et al. (2013) CXCL12/CXCR4
axis promotes mesenchymal stem cell mobi-
lization to burn wounds and contributes to
wound repair. J Surg Res 183:420–5
Kalatskaya I, Berchiche YA, Gravel S et al. (2009)
AMD3100 is a CXCR7 ligand with allosteric
agonist properties. Mol Pharmacol 75:1240–7
Maksym RB, Tarnowski M, Grymula K et al. (2009)
The role of stromal-derived factor-1–CXCR7
axis in development and cancer. Eur J Phar-
macol 625:31–40
Nishimura Y, Ii M, Qin G et al. (2012) CXCR4
antagonist AMD3100 accelerates impaired
wound healing in diabetic mice. J Invest
Dermatol 132:711–20
Petit I, Szyper-Kravitz M, Nagler A et al. (2002) G-
CSF induces stem cell mobilization by
decreasing bone marrow SDF-1 and up-reg-
ulating CXCR4. Nat Immunol 3:687–94
COMMENTARY
www.jidonline.org 2507
Rabbany SY, Pastore J, Yamamoto M et al. (2010)
Continuous delivery of stromal cell-
derived factor-1 from alginate scaffolds
accelerates wound healing. Cell Transplant
19:399–408
Sarkar A, Tatlidede S, Scherer SS et al. (2011)
Combination of stromal cell-derived factor-
1 and collagen-glycosaminoglycan scaffold
delays contraction and accelerates
reepithelialization of dermal wounds in
wild-type mice. Wound Repair Regen
19:71–9
Takekoshi T, Wu X, Mitsui H et al. (2013) CXCR4
negatively regulates keratinocyte proliferation
in IL-23-mediated psoriasiform dermatitis.
J Invest Dermatol 133:2530–7
Toksoy A, Muller V, Gillitzer R et al. (2007)
Biphasic expression of stromal cell-derived
factor-1 during human wound healing.
Br J Dermatol 157:1148–54
Xu X., Zhu F., Zhang M. et al. (2013) Stromal
cell-derived factor-1 enhances wound
healing through recruiting bone marrow-
derived mesenchymal stem cells to the
wound area and promoting neovascu-
larization. Cells Tissues Organs 197:
103–13
COMMENTARY
2508 Journal of Investigative Dermatology (2013), Volume 133
